CDR3δ-grafted γ 9δ2T cells mediate effective antitumor reactivity

Cellular and Molecular Immunology

Volumn 9, Issue 2, 2012, Pages 147-154

  Zhao, Hui ^a   Xi, Xueyan ^a   Cui, Lianxian ^a   He, Wei ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

T cells; CDR3 grafted 9 2TCR; tumor immunotherapy

Indexed keywords

T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY STRUCTURE; ANTIGEN RECOGNITION; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA MODIFICATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE TRANSFER; MOUSE; NONHUMAN; OVARY CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE SUBPOPULATION; THERAPY EFFECT; TUMOR CELL DESTRUCTION; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; CELL PROLIFERATION; CELLS, CULTURED; COMPLEMENTARITY DETERMINING REGIONS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MICE; MICE, NUDE; MUTATION; OVARIAN NEOPLASMS; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; TRANSGENES; TUMOR MICROENVIRONMENT; UTERINE CERVICAL NEOPLASMS;

ANIMALIA; MUS MUSCULUS;

EID: 84863270770     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2011.28     Document Type: Article

References (37)

1. Peng L, Shu SKrauss JC. Treatment of subcutaneous tumor with adoptively transferred T cells. Cell Immunol 1997; 178: 24-32. (Pubitemid 27250277)
2. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318-1321. (Pubitemid 16002234)
3. Plautz GE, Bukowski RM, Novick AC, Klein EA, Kursh ED, Olencki TE et al T-cell adoptive immunotherapy of metastatic renal cell carcinoma. Urology1999; 54: 617-623; discussion 623-614.
4. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL et al Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001; 24: 363-373. (Pubitemid 32825868)
5. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666-675. (Pubitemid 37328821)
6. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers antitumor reactivity. J Immunol 1999; 163: 507-513. (Pubitemid 29295880)
7. Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, TheoretMRet al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 2003; 171: 3287-3295. (Pubitemid 37093556)
8. Hughes MS, Yu YY, Dudley ME, Zheng Z, Robbins PF, Li Y et al Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther2005; 16: 457-472. (Pubitemid 40647143)
9. Stanislawski T, Voss RH, Lotz C, Sadovnikova E, Willemsen RA, Kuball J et al. Circumventing tolerance to a human MDM2-deriv ed tumor antigen by TCR gene transfer. Nat Immunol 2001; 2: 962-970. (Pubitemid 32976170)
10. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, SherryRM et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129. (Pubitemid 44547756)
11. Kessels HW, Wolkers MC, Schumacher TN. Adoptive transfer of T-cell immunity. Trends Immunol 2002; 23: 264-269. (Pubitemid 34499564)
12. Hayday AC. Gammadelta cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000; 18: 975-1026. (Pubitemid 30365402)
13. Kabelitz D, Wesch D, He W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res 2007; 67: 5-8. (Pubitemid 46142752)
14. Scotet E, Martinez LO, Grant E, Barbaras R, Jeno P, GuiraudMet al Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPaserelated structure and apolipoprotein A-I. Immunity 2005; 22: 71-80. (Pubitemid 40143452)
15. Chen H, He X, Wang Z, Wu D, Zhang H, Xu C et al. Identification of human T cell receptor gammadelta-recognized epitopes/proteins via CDR3delta peptide-based immunobiochemical strategy. J Biol Chem 2008; 283: 12528-12537.
16. Kang N, Zhou J, Zhang T, Wang L, Lu F, Cui Y et al. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood. Cancer Biol Ther 2009; 8: 1540-1549.
17. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003; 102: 200-206. (Pubitemid 36759655)
18. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G et al. Targeting human gammadelta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007; 67: 7450-7457. (Pubitemid 47206575)
19. Wang Z, Zhang T, Hu H, Zhang H, Yang Z, Cui L et al. Targeting solid tumors via T cell receptor complementarity-determining region 3delta in an engineered antibody. Cancer Lett 2008; 272: 242-252.
20. Yuasa T, Sato K, Ashihara E, Takeuchi M, Maita S, Tsuchiya N et al Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunol Immunother 2009; 58: 493-502.
21. van der Veken LT, Hagedoorn RS, van Loenen MM, Willemze R, Falkenburg JH, Heemskerk MH. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity. Cancer Res 2006; 66: 3331-3337.
22. van der Veken LT, Coccoris M, Swart E, Falkenburg JH, Schumacher TN, Heemskerk MH. Alpha beta T cell receptor transfer to gamma delta T cells generates functional effector cells without mixed TCR dimers in vivo. J Immunol 2009; 182: 164-170.
23. Rock EP, Sibbald PR, Davis MM, Chien YH. CDR3 length in antigen-specific immune receptors. J Exp Med 1994; 179: 323-328. (Pubitemid 24012999)
24. Adams EJ, Strop P, Shin S, Chien YH, Garcia KC. An autonomous CDR3delta is sufficient for recognition of the nonclassical MHC class I molecules T10 and T22 by gammadelta T cells. Nat Immunol 2008; 9: 777-784. (Pubitemid 351859161)
25. Xu C, Zhang H, Hu H, He H, Wang Z, Xu Y, et al. Gammadelta T cells recognize tumor cells via CDR3delta region. Mol Immunol 2007; 44: 302-310. (Pubitemid 44308356)
26. Xi X, Guo Y, Chen H, Xu C, Zhang H, Hu H et al. Antigen specificity of gammadelta T cells depends primarily on the flanking sequences of CDR3delta. J Biol Chem 2009; 284: 27449-27455.
27. Bunnell BA, Muul LM, Donahue RE, Blaese RM, Morgan RA. High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc Natl Acad Sci USA 1995; 92: 7739-7743.
28. Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier JF, Scotet E et al. V gamma 9V delta 2 T cell response to colon carcinoma cells. J Immunol 2005; 175: 5481-5488. (Pubitemid 41456435)
29. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2007; 56: 469-476. (Pubitemid 46204533)
30. Sato K, Kimura S, Segawa H, Yokota A, Matsumoto S, Kuroda J et al. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 2005; 116: 94-99. (Pubitemid 40827760)
31. He X, Chen H, Wu D, Cui L, He W. Tandem-epitope peptide: a novel stimulator for gammadeltaT cells in tumor immunotherapy. Cancer Lett; 288: 86-93.
32. Shin S, El-Diwany R, Schaffert S, Adams EJ, Garcia KC, Pereira P et al Antigen recognition determinants of gammadelta T cell receptors. Science 2005; 308: 252-255. (Pubitemid 40558860)
33. Dalton JE, Howell G, Pearson J, Scott P, Carding SR. Fas-Fas ligand interactions are essential for the binding to and killing of activated macrophages by gamma delta T cells. J Immunol 2004; 173: 3660-3667. (Pubitemid 39280726)
34. Nakata M, Smyth MJ, Norihisa Y, Kawasaki A, Shinkai Y, Okumura Ket al. Constitutive expression of pore-forming protein in peripheral blood gamma/delta T cells: implication for their cytotoxic role in vivo. J Exp Med 1990; 172: 1877-1880.
35. Dieli F, Troye-Blomberg M, Ivanyi J, Fournie JJ, Krensky AM, Bonneville M et al. Granulysin-dependent killing of intracellular and extracellular Mycobacterium tuberculosis by Vgamma9/Vdelta2 T lymphocytes. J Infect Dis 2001; 184: 1082-1085. (Pubitemid 32955129)
36. Christmas SE, Meager A. Production of interferon-gamma and tumour necrosis factoralpha by human T-cell clones expressing different forms of the gamma delta receptor. Immunology 1990; 71: 486-492.
37. Poehlein CH, Hu HM, Yamada J, Assmann I, Alvord WG, Urba WJ et al. TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells. J Immunol 2003; 170: 2004-2013. (Pubitemid 36197421)